STOCK TITAN
  1. Home
  2. News
  3. CBUS

Cibus, Inc. - CBUS STOCK NEWS

Welcome to our dedicated page for Cibus news (Ticker: CBUS), a resource for investors and traders seeking the latest updates and insights on Cibus stock.

Cibus, Inc. (Nasdaq: CBUS) is a pioneering biotechnology company that focuses on developing and commercializing proprietary gene-editing technologies. At the heart of Cibus’ innovation is its Rapid Trait Development System (RTDS®), a cutting-edge gene-editing platform that integrates crop-specific cell biology with advanced gene-editing techniques. The company's mission is to enhance plant traits to address crucial farming challenges related to productivity, disease resistance, and environmental sustainability.

One of Cibus’ key projects includes the development of herbicide tolerance traits in rice. The recent field trials for the HT1 and HT3 traits have shown promising results, meeting or exceeding performance expectations. This success has led to the first transfer of customer seeds containing these traits, marking a significant step in the company's commercial journey.

In addition, Cibus has made notable progress with its Pod Shatter Reduction (PSR) trait in canola. The PSR trait aims to minimize yield losses due to pod shattering, a common issue in canola farming. The successful field trials have enabled the transfer of PSR traits to multiple seed developers, with commercial hybrid sales expected as early as 2025.

Cibus is also at the forefront of legislative changes in Europe, supporting new regulations for New Genomic Techniques (NGTs) that classify certain gene-editing methods as ‘Conventional-like’. This regulatory recognition is expected to facilitate the commercial adoption of Cibus’ gene-edited traits across the European Union.

Recently, Cibus announced a strategic partnership with Loveland Products Inc. to commercialize herbicide tolerance traits in rice for the southern US market. This collaboration underscores Cibus’ commitment to providing innovative solutions to pressing agricultural challenges.

Cibus’ proprietary Trait Machine™ System is integral to its technology breakthrough. This system standardizes the gene-editing process, allowing precise modifications in a seed company’s elite germplasm without using foreign DNA or transgenes. The Trait Machine is currently operational for canola and rice, with broader applications anticipated in the future.

Overall, Cibus is revolutionizing plant breeding with its high-throughput gene-editing technology, addressing critical agricultural challenges, and paving the way for more sustainable and productive farming practices globally.

News

Cibus 2023 Field Trial Results Move Developed Traits Closer to Product Sales

Rhea-AI Summary
Cibus, Inc. (NASDAQ: CBUS) has announced successful field trials for its rice herbicide tolerance traits, HT1 and HT3, and its canola Pod Shatter Reduction (PSR) trait. The company is preparing for the commercial launch of these traits, with field scale demonstrations in the US Mid-South and plans to integrate the traits into product lines. Cibus also reported that its PSR trait in canola seed developer genetics performed well, leading to the first hybrid sales as early as 2025. The company aims to change the canola/WOSR market by broadly licensing its PSR trait to seed developers globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
none
-
News

Cibus Announces Major Breakthrough in Wheat Regeneration from Single Cells

Rhea-AI Summary
Cibus, Inc. (NASDAQ: CBUS) successfully regenerates plants from single cells in a wheat cultivar, representing a major breakthrough for the company and the seed industry. This achievement accelerates trait development in wheat, a key crop for global food security, and demonstrates Cibus' success in developing scalable high throughput breeding platforms for major crops.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.27%
Tags
none
-
News

Cibus Enters into a Latin America Collaboration Agreement with Interoc to deliver rice growers an innovative rice weed control system

Rhea-AI Summary
Cibus, Inc. (Nasdaq: CBUS) collaborates with Interoc to introduce two herbicide tolerance traits for rice growers in Latin America, aiming to address weed management challenges and improve yields in the region.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.46%
Tags
none
News

TMC Subsidiary NORI Shares Preliminary Findings on Environmental Impacts of Pilot Nodule Collection System Test

Rhea-AI Summary
Cibus, Inc. (NASDAQ: CBUS) acknowledges the European Union notification to World Trade Organization (WTO) members on the European Commission proposal for regulation of plants obtained from New Genomic Techniques (NGTs). The proposal aims to regulate NGT products similar to conventional varieties, aligning EU policy with trading partners in North and South America, Australia, India, and Japan. The proposal was adopted by the EU College of Commissioners and is currently under review in committees of the European Parliament and by Ministers of Member States in the Council of the European Union. Members of the European Parliament are expected to vote on the proposal in January 2024, with an adoption date proposed in July 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
none
-
News

Cibus Announces $20.3 Million Registered Direct Offering

Rhea-AI Summary
Cibus, Inc. (Nasdaq: CBUS) has priced an underwritten offering of 2,106,723 shares of its Class A Common Stock and Pre-Funded Warrants to purchase up to 50,000 shares of its Class A Common Stock. The offering price is $9.00 per share, with gross proceeds estimated to be approximately $20.3 million. The offering is expected to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
offering
-
News

European Union Notifies Trading Partners on the Proposal for the Regulation of Plants Obtained from New Genomic Techniques

Rhea-AI Summary
Cibus, Inc. (NASDAQ: CBUS) acknowledges the European Union's proposal for the regulation of plants obtained from New Genomic Techniques (NGTs). The proposal aims to bring EU policy closer to that of trading partners in North and South America, Australia, India, and Japan. The proposal is a result of a European Commission study, requested by EU Member States, which concluded that EU GMO legislation was not fit for purpose in relation to applications of NGTs in plants. The proposal, currently under review, describes a category of NGTs producing modifications that could be obtained in nature or by conventional breeding, which would be regulated in the same way as conventional varieties. The proposal is scheduled for adoption in July 2024, with additional implementing acts required to be passed within 24 months for the new legislation to become fully operational.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.34%
Tags
none
News

Cibus Announces New Publication: Industrial Scale Gene Editing in Brassica napus

Rhea-AI Summary
Cibus, Inc. (NASDAQ: CBUS) has announced the publication of a paper in the International Journal of Plant Biology, showcasing case studies of improving oleic oil content and developing pod shatter reduction in Brassica napus using gene editing tools on an industrial scale. The company's Trait Machine™ System has led to breakthroughs in breeding and scale, reducing timelines to develop new traits from as much as 16 years to approximately three to five years. Cibus is driving the speed and number of edited seed transfers of its pod shatter reduction trait to major seed company customers, with increased throughput allowing delivery of multiple elite genetic lines integrating into advanced commercial breeding programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
none
-
News

Cibus Reports Third Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Cibus, Inc. (Nasdaq: CBUS) announced its financial results for the quarter ended September 30, 2023, and provided a business update. The company completed extensive field trials for its PSR trait in canola and HT1 and HT3 in rice. It also reported continued progress of its high-throughput soybean editing system and two advanced traits for Sclerotinia resistance and HT2. Cibus launched strategic realignment and cost savings initiatives to focus on advancing late-stage activities. Initial UK field trials for its PSR trait in WOSR are underway, and the company is accelerating its PSR trait in the European market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.76%
Tags
earnings
-
News

European Parliament Releases Draft Report on the Proposal for the Regulation of Plants Obtained from New Genomic Techniques

Rhea-AI Summary
Cibus, Inc. supports the European Commission's proposal to regulate plants obtained from new genomic techniques (NGTs) and their food and feed. The proposed regulation introduces a 'Conventional-like' category for NGT products, aligning EU policy with trading partners in North and South America, Australia, and Japan. The report highlights the potential of NGTs to enhance agriculture and food production in Europe. Cibus' gene editing platform products, such as disease-resistant canola and oilseed rape with reduced seed losses, would fall under the 'Conventional-like' category.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
none
News

Cibus to Report Third Quarter 2023 Financial Results on November 9, 2023 and Host Conference Call

Rhea-AI Summary
Cibus, Inc. (Nasdaq: CBUS) will report its third quarter 2023 financial results on November 9, 2023. The company's management team will host a conference call and webcast at 4:30 p.m. ET to discuss the financial results and other company updates. Interested individuals can access a dial-in replay of the call or a live audio webcast with accompanying slides on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
conferences earnings

FAQ

What is the current stock price of Cibus (CBUS)?

The current stock price of Cibus (CBUS) is $4.53 as of November 15, 2024.

What is the market cap of Cibus (CBUS)?

The market cap of Cibus (CBUS) is approximately 122.3M.

What is the main focus of Cibus, Inc.?

Cibus, Inc. focuses on developing and commercializing gene-editing technologies to enhance plant traits, addressing productivity, disease resistance, and sustainability issues in farming.

What is the Rapid Trait Development System (RTDS®)?

RTDS® is Cibus’ proprietary gene-editing platform that integrates crop-specific cell biology with advanced gene-editing technologies to develop precise plant traits without using foreign DNA or transgenes.

What recent achievements has Cibus made in rice farming?

Cibus has successfully developed herbicide tolerance (HT1 and HT3) traits for rice, which have met or exceeded performance expectations in field trials and are now being transferred to seed developers for commercial use.

How is Cibus addressing the issue of pod shatter in canola?

Cibus has developed a Pod Shatter Reduction (PSR) trait for canola, which has shown positive field trial results and is being transferred to multiple seed developers, with commercial hybrid sales expected by 2025.

What recent legislative changes in Europe support Cibus’ technology?

The European Parliament recently voted in favor of new regulations for New Genomic Techniques (NGTs), classifying certain gene-editing methods as ‘Conventional-like’, facilitating the adoption of Cibus’ traits in the EU.

What is the Trait Machine™ System?

The Trait Machine™ System is Cibus’ standardized end-to-end gene-editing process that allows precise modifications in a seed company’s elite germplasm, ensuring the development of high-quality plant traits.

What is the significance of Cibus’ partnership with Loveland Products Inc.?

Cibus has partnered with Loveland Products to commercialize herbicide tolerance traits in rice, focusing on the southern US market to address weed management challenges.

How does Cibus plan to address Sclerotinia resistance in crops?

Cibus is developing multiple modes of action for Sclerotinia (White Mold) resistance in canola and other crops, with the goal of providing durable resistance and reducing crop losses.

Does Cibus use genetically modified organisms (GMOs) in its technology?

No, Cibus’ gene-editing technology does not use foreign DNA or transgenes, making its developed traits indistinguishable from those produced by conventional breeding.

What crops does Cibus focus on for its gene-editing technology?

Cibus focuses on major global row crops with large acreage such as canola, corn, rice, soybean, and wheat.

Stock CBUS logo
Cibus, Inc.

Nasdaq:CBUS

CBUS Rankings

#4220 Ranked by Market Cap
N/A Ranked by Dividends

CBUS Stock Data

122.30M
26.46M
24.23%
31.13%
7.03%
Biotechnology
Agricultural Chemicals
Link
United States of America
SAN DIEGO